9051 Mira Mesa Blvd, #910094
San Diego, CA 92191
Tel: 760-390-3989

KRT20 Human

Cytokeratin 20 Human Recombinant
RCP1199

Product Overview

Name	KRT20 Human
Description	
Cytokeratin 20 Human Recombinant	
Accession (Primary)	P35900
Synonyms	
Keratin type I cytoskeletal 20, Cytokeratin-20, CK-20, Keratin-20, K20, Protein IT, KRT20, CD20, CK20, KRT21, MGC35423.	
Introduction	
KRT20 is a member of the keratin family. The keratins are intermediate filament proteins responsible for the structural integrity of epithelial cells and are subdivided into cytokeratins and hair keratins. The type I cytokeratins consist of acidic proteins which are arranged in pairs of heterotypic keratin chains. This cytokeratin is a major cellular protein of mature enterocytes and goblet cells and is specifically expressed in the gastric and intestinal mucosa. The type I cytokeratin genes are clustered in a region of chromosome 17q12-q21.	
Source	
Escherichia Coli.	
Physical Appearance	
Sterile Filtered White lyophilized (freeze-dried) powder.	
Formulation	
The protein (1mg/1ml) was lyophilized after from a sterile solution containing 30mM Tris-HCL pH-8, 9.5M urea, 2mM DDT, 2mM EDTA and 10mM methylammonium chloride.	
Stability	
Lyophilized KRT20 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution KRT20 should be stored at 4°C between 2-7 days and for future use below -18°C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please prevent freeze-thaw cycles.	
Purity	
Greater than 95.0% as determined by SDS-PAGE.	
Solubility	
It is recommended to reconstitute the lyophilized KRT20 in sterile 18MΩ-cm H2O not less than 100 µg/ml, which can	

9051 Mira Mesa Blvd, #910094
San Diego, CA 92191
Tel: 760-390-3989

then be further diluted to other aqueous solutions.

Reconstitution to filaments

Performed by mixing equimolar amounts of cytokeratins of type I and type II at concentrations of approx. 0.5 mg/ml, both dissolved in 9.5 M urea buffer (see above). Protofilaments and filament complexes are obtained by dialyzing the resulting polypeptide solution stepwise to a concentration of 4 M urea and then to low salt condition (50 mM NaCI, 2 mM dithiothreitol, 10 mM Tris-HCI, pH 7.4). For immunization purposes, the solution can be further dialyzed against PBS (phosphate buffered saline, e.g. Dulbecco's PBS).

Precautions

KRT20 Human is for research use only and not for use in diagnostic or therapeutic procedures.

Target Information: (P35900)